🇺🇸 FDA
Patent

US 7612037

Cross-linked glycopeptide-cephalosporin antibiotics

granted A61KA61K31/545A61K38/00

Quick answer

US patent 7612037 (Cross-linked glycopeptide-cephalosporin antibiotics) held by Theravance, Inc. expires Mon Oct 29 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance, Inc.
Grant date
Tue Nov 03 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 29 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/545, A61K38/00, A61P, A61P31/00